Long-Term Outcomes and Safety Trends of Autologous Stem-Cell Transplantation in Non-Hodgkin Lymphoma: A Report From A Tertiary Care Center in India ascopubs.org/doi/full/10.12…

This week's 🧵 WONDER DRUG: This Punjabi microbiologist dedicated his life to studying a compound. It saved millions of lives—including, for a while, his own.

Definitive CCRT HNSCC,wkly DDP is non inferior to 3wkly DDP,better tolerated,less toxicity and should be 1 of standard. Congrats Atul Sharma for leading this multicentre RCT.Amol Patel Prashant Mehta Aparna Sharma Dr (Prof). Vijay Patil AIIMS, New Delhi ISMPO Young Oncologists Group India🇮🇳 ASCO

Amazing first night in Chicago with mentors from AIIMS! Raja Pramanik Atul Sharma All set for the next 4 days! #ASCO22

This is big and could lead to a tectonic change in the management of #ColorectalCancer 🚀 Presented at #ASCO22 & out in the ⁦NEJM⁩ ➡️Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II #crcsm OncoAlert 🚨#PrecisionMedicine nejm.org/doi/full/10.10…

A large prospective study of genetic determinants of #breastcancer from India found a high prevalence of variants of uncertain significance Abhenil Mittal Olufunmilayo Olopade Raja Pramanik Atul Batra Koushik Sinha Deb ecancer.org/en/journal/art…

New paper just published in ecancer ecancer. A word of appreciation for the journal- timely peer review, very good comments and excellent publishing process; highly recommended to all prospective authors trying to find a home for their papers!

Full circle😇 From reading this book (popularly called as “Casciato”) as a medical oncology aspirant to now becoming a contributor to the same book.😀🤩 Thank you Atul Batra ; South East Asia editor of “The Manual of Clinical Oncology” for this massive opportunity!

EMF(Erlotinib,MTX,5FU), a new option for platinum ref RMHNSCC esp in LMIC. Our study introduces this new regimen: good ORR, DCR & safety profile. Kudos to Dr. Annie Annie K Baa.Translational work on CTCs & cfDNA to follow.Atul Sharma ecancer.org ecancer.org/#.YzXOemyNEA0.…

Our work on COVID-19 infection in Cancer patients done in 3 centres including AIIMS. COVID mortality was 17% in oncology patients, much higher than non oncology patients. pubmed.ncbi.nlm.nih.gov/36348601/

Wonderful two days spent with all generations of luminaries and doyens of oncology in India at the AIIMS, New Delhi Medical Oncology Annual RESMO and Alumni meet! Reminiscing old times ,brainstorming on academics and getting inspired at IRCH and NCI. Atul Sharma Atul Batra

Day 2 nick Jhajjar

A great amalgamation of 120+ Alumni at the Mecca of teaching in #MedicalOncology, #AIIMS, #NewDelhi. 📖📚 May the flame of knowlwdge ignited here shine far and wide. 🕯🕯🔥 AIIMS, New Delhi Atul Sharma Atul Batra Prabhat Malik Ranjit Kumar Sahoo Aparna Sharma Raja Pramanik

AIIMS Alumni Meeting # Nostalgia

👇will change my practice today RDBPCT, N= 124 #gastric #HPB #lung #cancer Journal of Clinical Oncology 📌 Olanzapine 2.5mg/day ⬆️ appetite, weight and QoL ⭐️ simple inexpensive intervention for a common and difficult problem for our pts with #GIcancer Congrats to the study team 🇮🇳 🙏

How to read an HLA report? A thread 🧵✍️on understating HLA typing for BMT Key slides from my talk at #ISBMT Annual Meeting (1/7) ISBMT_UPDATES ASTCT Transplantation and Cellular Therapy Journal ISMPO ISHBT

Congratulations Atul Batra @TuttsAkhil for this practice changing study of topical diclofenac in Capecitabine induced HFS.#AIIMS

Some more ‘India Shining moments from #ASCO2023 ( my personal favourites ) ASCO The ASCO Post Journal of Clinical Oncology 1 - Steroid free antiemesis Venky

Happy to share our translational study of CTCs in R/R HNSCC . Every grateful to my mentors Atul Sharma , Raja Pramanik and AIIMS, New Delhi. Thanks to ecancer for the seamless , smooth process again .

D-TORCH full paper out in Journal of Clinical Oncology 👯‍♂️ Breast or GI cancer Capecitabine treatment N=263 👉Diclofenac gel or Placebo 🎯G2/3 HFS: 3.8% v 15.0% 👉Less frequent dose reduction 👉Better QoL @TuttsAkhil Atul Sharma Sameer Bakshi ascopubs.org/doi/10.1200/JC…